Search

Displaying results 7391 - 7400 of 9314 in total
  1. Drug

    Pradigastat

    go.drugbank.com/drugs/DB12866
    Investigational

    Pradigastat has been used in trials studying the treatment of Non-alcoholic Fatty Liver Disease (NAFLD).

  2. Drug

    Namodenoson

    go.drugbank.com/drugs/DB12885
    Investigational

    Namodenoson has been used in trials studying the treatment of Chronic Hepatitis C and Hepatocellular Carcinoma.

  3. Drug

    Dimiracetam

    go.drugbank.com/drugs/DB13018
    Investigational

    Dimiracetam has been used in trials studying the treatment of AIDS, Neuropathy, and Acquired Immunodeficiency Syndrome.

  4. Drug

    Lanifibranor

    go.drugbank.com/drugs/DB14801
    Investigational

    Lanifibranor is under investigation in clinical trial NCT03008070 (Phase 2b Study in NASH to Assess IVA337).

  5. Drug

    Konjac mannan

    go.drugbank.com/drugs/DB14963
    Investigational

    Konjac mannan is under investigation in clinical trial NCT01709955 (The Effects of Glucomannan on Weight Loss).

  6. Drug

    Suvratoxumab

    go.drugbank.com/drugs/DB15172
    Investigational

    Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).

  7. Drug

    Suvodirsen

    go.drugbank.com/drugs/DB17940
    Investigational

    Suvodirsen is an antisense oligonucleotide that has been investigated for the treatment of Duchenne muscular dystrophy.

  8. Drug

    ART5803

    go.drugbank.com/drugs/DB18379
    Investigational

    ART5803 is a humanized one-armed monoclonal antibody with a high affinity for the NMDA receptor.

  9. Drug

    Rugonersen

    go.drugbank.com/drugs/DB18662
    Investigational

    Rugonersen is a locked nucleic acid antisense oligonucleotide under investigation for the treatment of Angelman Syndrome.

  10. Drug

    Veverimer

    go.drugbank.com/drugs/DB18977
    Investigational

    Veverimer is under investigation in clinical trial NCT03390842 (Long-term Safety Extension to Study TRCA-301).